Research coauthored by RTI Health Solutions researchers will be presented at the 2021 Virtual AMCP Conference.
Budget impact of introducing neratinib for third-line treatment of human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States. Anderson S, Carrico J, Brodtkorb T-H, Lalla D, Brufsky A. Poster
Pharmacological costs for the treatment of eosinophilic esophagitis in the USA. Davis AE, Jiang J, Talbird SE, Turpin R, Mellott CE, Boules M, Wojtowicz AM, Fan T. Poster
Model structure considerations for cost-effectiveness evaluation of C3 inhibitor pegcetacoplan vs. C5 inhibitor in patients with paroxysmal nocturnal hemoglobinuria. Hillman P, Jia X, Knight C, Sarda SP, Mody-Patel N, Intorcia M, Dingli DJ. Poster
Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HER2-overexpressed/amplified HR+ breast cancer who initiated neratinib within 1 year of completing trastuzumab in the US. Brodtkorb T-H, McDade C, Lalla D, Holmes FA.
Direct and indirect costs of intravenous infusions of edaravone among patients with amyotrophic lateral sclerosis. Ronquest NA, Lucas A, Ciepielewska M, Miles L, Paret K, Hagan M. Poster